Abstract
Breast cancer remains one of the “big killers” worldwide, even when the slight reduction in mortality figures of these last few years is taken into account. Given the current results of conventional cancer treatment, there are good reasons for improving the available preventive strategies and thus for exploring new ways in this direction. At present, prospects for breast cancer prevention are being developed in three main areas: (a) lifestyle, to study various risk factors, including delayed first pregnancy and number of pregnancies; (b) genetics, to understand the real importance of familial breast cancer and of genetic testing; and (c) chemoprevention, to identify agents potentially able to inhibit the development of invasive cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baserga R (1995) The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55:249–252
Bernstein L, Ross RK, Lobo RA et al (1987) The effects of moderate physical activity on menstrual cycle patterns in adolescence: implications for breast cancer prevention. Br J Cancer 55:681–685
Cancer Research Campaign Breast Cancer Trials Group (1992) The effect of adjuvant tamoxifen — the latest results from the Cancer Research Adjunct Breast Trial. Eur J Oncol 28A:904–907
Coezy E, Borgna JL, Rochefort H (1982) Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42:317–323
Colditz GA, Rosner BA, Speizer FE et al (1996) Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 88:365–371
Costa A, Malone W, Perloff M et al (1989) Tolerability of the synthetic retinoid fenretinide (HPR). Eur J Cancer Clin Oncol 25:805–808
Costa A, Formelli F, Chiesa F et al (1994) Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 54 Suppl 7:2032–2037
Costantino JP, Kuller LH, Ives DG et al (1997) Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89:776–782
Decensi A, Torrisi R, Polizzi A et al (1994) Effect of the synthetic retinoid fenretinide on dark-adaptation and the ocular surface. J Natl Cancer Inst 86:105–110
Decensi A, Costa A, De Palo G et al (1997) Retinoid-menopause interactions in a breast cancer prevention trial. Am Assoc Cancer Res Proc 38:529
Delmas PD, Bjarnason NH, Mitlak BH et al (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:23
Fanjul A, Dawson MI, Hobbs PD et al (1994) A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372:107–111
Fisher B, Costantino JP, Redmond CK et al (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–537
Fisher B, Costantino JP, Redmond C et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. J Engl J Med 320:479–484
Formelli F, Clerici M, Campa T et al (1993) Five year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentration. J Clin Oncol 11:2036–2042
Friedman MA, Trimble EL, Abrams JS (1994) Tamoxifen: trials, tribulations, and trade-offs. J Natl Cancer Inst 86:478–479
He JH, Shut HAJ (1997) Indole-3-carbinol inhibits DNA adduct formation of the dietary carcinogen, 2-amino-l-methyl-6-phenylmidazo[4,5-b]pyridine in female F344 rats. Am Assoc Cancer Res Proc 38:371
Jordan VC (1995) Tamoxifen tumorigenicity: a predictable concern. J Natl Cancer Inst 87:623–626
Jordan VC, Lababidi MK, Langan-Fahey S (1991) Suppression of mouse mammary tumorigenesis by long term tamoxifen therapy. J Natl Cancer Inst 83:492–496
Khan SA, Rogers MAM, Khurama KK et al (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90:1
Knekt P (1991) Role of vitamin E in the prophylaxis of cancer. Ann Med 23:3–12
Lotan R (1995) Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst 87:1655–1657
Lubet RA, Bowden C, De Coster R et al (1997) Vorozole: effects on MNU-induced rat mammary tumors. Am Assoc Cancer Res Proc 38:372
Maltoni C, Pinto G, Paladini G (1988) Project of experimental bioassays on chemoprevention agents performed at the Bologna Institute of Oncology; report on tamoxifen control of spontaneous mammary tumours on Sprague-Dawley rats. Cancer Invest 6:643–658
Metha RG, Moon RC, Hawthorne M et al (1991) Distribution of fenretinide in the mammary gland of breast cancer patients. Eur J Cancer 27:138–141
Moon RC, Thompson HJ, Becci PJ et al (1979) N-(4-hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 39:1339–1346
Osborne MP, Telang NT (1991) Primary prevention of breast cancer. In: Bland KI, Copeland EM (eds) The breast: comprehensive management of benign and malignant diseases. Saunders, Philadelphia, pp 246–261
Pollack M, Hankinson S (1998) Biology of breast cancer risk and prognosis. Eur J Cancer Suppl 1:4
Pollack M, Costantino J, Polychronacos C et al (1990) Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82:1693–1697
Powles TJ, Hickish T, Kanis JA et al (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and post-menopausal women. J Clin Oncol 14:78–84
Prentice R, Thompson D, Clifford C et al (1990) Dietary fat reduction and plasma estradiol concentration in healthy postmenopausal women. J Natl Cancer Inst 82:129–134
Rutqvist LE, Johansson H, Signomklao T et al (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87:645–651
Schrag D, Kuntz KM, Garber JE et al (1997) Decision analysis — effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336:1465–1471
Sporn MB (1991) Carcinogenesis and cancer: different perspectives of the same disease. Cancer Res 51:6215–6218
Sporn MB, Newton DL (1979) Chemoprevention of cancer with retinoids. Fed Proc 38:2528–2534
Sporn MB, Suh N, Peer C et al (1997) LY353381 · HCI, a new benzothiophene for chemoprevention of brast cancer. Am Assoc Cancer Res Proc 38:500
Stearns V, Gelmann EP (1998) Does tamoxifen cause cancer in humans? J Clin Oncol 16:719–722
Torrisi R, Pensa F, Orengo MA et al (1993) The synthetic retinoid fenretinide lowers plasma IGF-I levels in breast cancer patients. Cancer Res 53:4769–4771
Veronesi U, for the Italian Tamoxifen Prevention Study (1995) Prevention of breast cancer with tamoxifen: the Italian study in hysterectomized women. Breast 4:267–272
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Costa, A., Bonanni, B., Manetti, L., Gonzaga, A.G., Torrisi, R., Decensi, A. (1998). Prevention of Breast Cancer: Focus on Chemoprevention. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Primary Breast Cancer VI. Recent Results in Cancer Research, vol 152. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45769-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-45769-2_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-45771-5
Online ISBN: 978-3-642-45769-2
eBook Packages: Springer Book Archive